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ABSTRACT
Background: Obstructive sleep apnoea–hypopnoea syndrome (OSAHS) carries substantial negative health
consequences. This study examines factors affecting mortality and morbidity according to continuous
positive airway pressure (CPAP) use and predictors affecting CPAP adherence in a longitudinal cohort of
OSAHS patients.
Materials and methods: This prospective, cohort study comprised 4502 patients who were diagnosed with
OSAHS at a tertiary sleep disorders centre between 1982 and 2003. Of these, 1174 patients completed
follow-up in 2012. Data collected included anthropometric, sleep and demographic characteristics,
including comorbidities, ongoing medications and CPAP adherence. Patients were followed up for an
average of 14.8±3.7 years.
Results: Imputation analysis showed that long-term CPAP users (>5 years) were 5.63 times more likely to
be alive at study end than non-CPAP users (95% CI: 4.83–6.58, p<0.001) and 1.74-times more likely than
short-term CPAP users (⩽5 years) (95% CI: 1.49–2.02, p<0.001). Females had a significantly higher
mortality rate during the follow-up period (26.8% versus 19.6%, p<0.001). Respiratory mortality was more
common in patients with OSAHS, in particular those who did not use CPAP, compared to the general
population (17.2% versus 12.2%, p=0.002 respectively), whereas deaths from cancer were less common
compared to the general population (16.2% versus 25.6%, p<0.001). Compared to CPAP users, non-CPAP-
users had a significantly increased incidence of type II diabetes mellitus (DMII) (27.9% versus 18.7%,
p=0.003), ischaemic heart disease (IHD) (25.5% versus 12.7%, p<0.001) and myocardial infarction (MI)
(14.7% versus 4.2%, p<0.001) at long-term follow-up.
Conclusions: Long-term CPAP use in men and women with OSAHS reduces mortality and decreases the
incidence of DMII and cardiovascular disease.
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In this first long-term prospective cohort study to use imputation analysis in OSAHS patients,
all-cause morbidity and mortality were significantly reduced in long-term CPAP users
(>5 years), and equivalent for both males and females https://bit.ly/3cKL2HK
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Introduction
Obstructive sleep apnoea–hypopnea syndrome (OSAHS) affects 3–7% of the population and is
characterised by excessive sleepiness and neurocognitive impairment [1]. Continuous positive airway
pressure (CPAP) therapy, the current gold-standard treatment for moderate-to-severe OSAHS, provides a
constant stream of pressurised air, maintaining the upper airway during sleep.
OSAHS is considered an independent risk factor for all-cause mortality and morbidity. Severe obstructive
sleep apnoea has been associated with a 1.9-times increased risk in all-cause mortality and 2.65-times
increased risk of cardiovascular mortality [2]. Previous cohort studies have shown female patients to have
a lower morbidity and mortality rate than males [3, 4]. CPAP has been shown to improve survival in male
patients [5], but less so in females [4].
Patients with severe, untreated OSAHS have been shown to have a higher incidence of cardiovascular
events compared to normal controls, and those treated with CPAP [5]. When compared with the general
population, OSAHS is more common in patients with existing coronary artery disease, with a reported
prevalence of 38–65% [6]. A large cohort study in Denmark showed negative predictors for survival to be
male sex, age ⩾60 years, no CPAP treatment, increased comorbidity burden (calculated using the Charlson
comorbidity index) and low educational level [4]. Another study also showed increasing age and comorbid
illness, namely cardiovascular, COPD and type II diabetes mellitus (DMII), to be predictors of mortality in
OSAHS patients [7].
The aim of the present study was to assess determinants of morbidity and mortality in a 30-year,
prospective cohort study of patients diagnosed with treatable OSAHS. We also hypothesised that lower
CPAP use would raise the risk of mortality and morbidity.
Material and methods
Study design
A single-centre prospective cohort study was carried out between 1982 and 2012. Follow-up took place for
a minimum of 7.5 years and a maximum of 30 years (average=14.8±3.7 years). All research was conducted
in accordance with the Declaration of Helsinki [8]. Mortality data were traced by the General Register
Office for Scotland [9].
Study subjects
A total of 6473 patients who had a sleep study at a tertiary sleep disorders centre between 1982 and 2003
were enrolled at baseline. Between 2010 and 2012, a follow-up questionnaire was sent to 5530 patients
(943 patients had died during the intervening period). Of 5530 questionnaires, 2857 (51.7%) were not
returned at all; 1047 (18.9%) were sent back due to a change of address; in 73 cases (1.3%) the patient was
unable to return the questionnaire and 25 patients refused to participate in the study (0.5%). In total, 1528
questionnaires were returned and were valid for analysis (27.6%). By 2012, the last year of the study, 68
more patients had died, raising the total number of deaths to 1011 patients.
Prior to analysis, all patients receiving noninvasive ventilation (NIV) or a mandibular repositioning splint
(MRS) were removed from the baseline database (n=94). Twelve patients were removed due to a diagnosis
of myotonic dystrophy. All patients with type II respiratory failure receiving bilevel ventilation (n=25) and
all patients with conditions implicating type II respiratory failure were removed (kyphoscoliosis (n=12),
myasthenia gravis (n=4), polio (n=6)). Another 1818 patients were removed due to a diagnosis of a sleep
disorder other than OSAHS. Thus, the baseline cohort of the study comprised 4502 OSAHS patients and
1174 at follow-up (questionnaire responders).
Methods
Data included basic demographic information and results of a clinical questionnaire completed prior to
the initial sleep clinic appointment. This questionnaire has been used routinely in the department for over
30 years and asks about age at presentation, height, weight, collar size, occupation, marital status, number
of children, smoking and alcohol, the three major reasons for attendance, comorbidities, current
medications, previous surgery of the upper airways and nose, the Epworth sleepiness score (ESS) [10],
driving history, symptoms consistent with sleep apnoea, impact on bed-mates of snoring and breathing
pauses, other symptoms consistent with sleep disorders, weight changes and sex life. In the majority of
patients (n=3481), OSAHS was diagnosed using polysomnography (PSG), while in the remaining cases, it
was diagnosed using ambulatory polygraphy (PG) (n=1021). PSG comprised electroencephalogram (EEG),
electrooculogram (EOC), chin electromyogram (EMG), nasal manometry, chest and abdominal wall
movements, oxygen saturation, snoring recording, body position and video monitoring during sleep,
whereas limited study comprised nasal manometry, chest and abdominal wall movements, oxygen
saturation and heart rate [10, 11]. OSAHS was diagnosed as an apnoea–hypopnoea index (AHI) of ⩾5 or
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an apnoea+hypopnoea per hour in bed (A+H) of ⩾25 plus an ESS of ⩾11 [10]. PSGs and PGs were
scored by experienced sleep physiologists according to the respective guidelines during the study period
[12, 13]. During the questionnaire follow-up phase (2010–2012) patients were sent a postal questionnaire
to assess health status. The questionnaires included questions regarding current height, weight, smoking/
alcohol history, comorbidities (including new medical, sleep and psychiatric conditions that had developed
since last review), medications currently prescribed, questions regarding driving and sleepiness and what
type of license the patient was using, subjective CPAP use in hours per night, which was verified
objectively using records as far as possible and questions regarding issues with CPAP irrespective of
whether the patients was still using or not. Patients who were no longer on CPAP were asked to respond
as to why they had stopped. Patients were also asked to complete an ESS.
Analysis
Analysis was carried out using SPSS Statistics 24.0 software (IBM Corp, Armonk, NY, USA). Continuous
variables are presented as a mean±SD and categorical variables as number and percentage. To separate
parametric from nonparametric variables, normality tests, using the Kolmogorov–Smirnov test, were
TABLE 1 Baseline characteristics of the obstructive sleep apnoea–hypopnoea syndrome
(OSAHS) cohort and cause of death split by sex
Characteristic Males (n=3580, 79.5%) Females (n=922, 20.5%) p-value
Length of follow-up years 14.8±3.7
(3579)
14.7±3.6
(920)
0.20
Age years 50.5±11.3
(3558)
51.8±13.8
(917)
0.001
Weight kg 97.2±21.4
(2485)
85.6±23.7
(644)
<0.001
BMI kg·m−2 31.8±6.7
(2466)
33.6±9.4
(635)
0.001
Smoking# cigarettes per day 14.7±15.8
(2250)
11.5±12.9
(576)
<0.001
Alcohol units per week 12.4±14.3
(2284)
3.8±6.4
(567)
<0.001
ESS n/24 13.2±4.9
(3069)
13.7±5.1
(778)
0.004
Partner-reported ESS n/24 7.3±4.8
(941)
8.8±5.7
(168)
0.003
AHI 38.9±36.5
(2758)
27.9±30.9
(736)
<0.001
A+H 45.0±21.9
(473)
38.4±24.2
(89)
0.003
CPAP¶ hours per night 4.6±2.9
(2282)
3.9±3.2
(471)
<0.001
OSAHS severity
Mild 734 (20.5%) 347 (37.6%) <0.001
Moderate 809 (22.6%) 206 (22.3%) 0.97
Severe 1688 (47.2%) 272 (29.5%) <0.001
CPAP use 2064 (57.7%) 409 (44.3%) <0.001
Mortality 702 (19.6%) 247 (26.8%) <0.001
Cause of death
Cardiovascular 280 (39.9%) 80 (32.4%) 0.037
Respiratory 114 (16.2%) 49 (19.8%) 0.20
Cancer 116 (16.5%) 38 (15.4%) 0.68
Accident/violent 14 (2.0%) 1 (0.4%) 0.13
Dementia 3 (0.4%) 3 (1.2%) 0.19
Other 62 (8.8%) 30 (12.2%) 0.13
Unknown 113 (16.1%) 46 (18.6%) 0.36
Data are presented as mean±SD (n) or n (%), unless otherwise stated. Statistical significance is at p<0.05/
25=0.002). OSAHS: obstructive sleep apnoea–hypopnoea syndrome; BMI: body mass index; ESS: Epworth
sleepiness scale; AHI: apnoea–hypopnoea index; A+H: apnoea+hypopnoea per hour in bed; CPAP:
continuous positive airway pressure. #: Current plus ex-smokers; ¶: Data are downloaded from CPAP
machine.
https://doi.org/10.1183/23120541.00057-2020 3
SLEEP | S. DODDS ET AL.
performed. Categorical variables were analysed using the Chi-squared test, whereas continuous variables
were analysed using the independent samples t-test for parametric variables and the Mann–Whitney
U-test for nonparametric variables. All tests were two-tailed and analysis for multiple comparisons was
undertaken. Significance was taken at p<0.05/n (n=number of groups, or when there were two groups,
n=number of comparisons). To search for variables affecting survival or adherence to CPAP treatment, a
univariate analysis was initially performed between the dependent variable and each independent variable
separately, followed by a multivariate backward regression analysis using the dependent variable and all the
independent variables that were statistically significant in univariate regression analysis. Kaplan–Meier
survival curves were used to analyse survival likelihood. For morbidity and mortality analyses we divided
the cohort in two groups: 1) those who had used CPAP continuously since their diagnosis (CPAP arm);
and 2) those who refused CPAP use plus those who initially used CPAP but eventually stopped using it
(No-CPAP arm).
Baseline data were further analysed using imputation analysis to emulate a randomised controlled trial
with full adherence, thereby removing immortal time bias [14]. Patients were initially assigned to CPAP
versus non-CPAP users at t=0. Clones were then assigned to either ‘short-term’ (CPAP use for ⩽5 years)
or ‘long-term’ (CPAP use for >5 years) groups in order to look at the effects of CPAP use on long-term
mortality. This grouping was carried out on the basis of trends discovered within the dataset, and
comparison with parameters set by similar cohort studies [15]. Artificial censoring ensures that clones
follow the assigned strategy through follow-up. Selection bias was eliminated by inverse probability
weighting [14]. Data were then used to calculate a relative risk ratio comparing patient mortality across the
three patient groups.
Results
A total of 4502 patients with a mean age of 50.8±11.8 years were included for analysis at baseline. Of
them, 3580 (79.5%) were male and 922 (20.5%) were female. Females were older and had a higher body
mass index (BMI), whereas males had a higher AHI, consumed more alcohol and smoked more. Of the
initial 4502 patients, 949 were known to have died by 2012. Despite males having significantly higher rates
of severe OSAHS, females had a significantly higher mortality rate during the follow-up period (26.8%
versus 19.6%, p<0.001). Women used CPAP significantly less compared to males, both as a percentage of
total and as hours per night (table 1).
Cardiovascular and respiratory events were more common causes of death in OSAHS patients compared
to the general Scottish population. For respiratory causes, the difference was statistically significant
(p=0.002) (table 2). Deaths from cancer were significantly less common in OSAHS patients compared to
the general population (16.2% versus 25.6%, p<0.001). During the follow-up period, 95.2% (n=903) of the
deaths occurred in the No-CPAP arm of the study, whereas 4.8% (n=46) occurred in the CPAP arm
(p<0.001) (table 2). Among causes of death, respiratory mortality was significantly higher in the No-CPAP
arm compared to the CPAP arm (17.9% versus 2.2%, p=0.006) (table 2).
The strongest predictor of mortality in both sexes was non-CPAP use (OR=16.8, p<0.001 for males,
OR=11, p<0.001 for females) (table 3). The coexistence of DMII at OSAHS diagnosis was also significant
TABLE 2 Cause of death split by CPAP use and comparison with the general Scottish population between 1982–2012
Cause of death OSAHS population (n=4502) General Scottish population p-value
On CPAP
(n=2473, 54.9%)
No CPAP
(n=2029, 45.1%)
p-value Total deaths
(n=949)
Total
deaths
(n≈1.5 million)
Cardiovascular 14 (30.4%) 346 (38.3%) 0.28 37.9% 35.9% 0.37
Respiratory 1 (2.2%) 162 (17.9%) 0.006 17.2% 12.2% 0.002
Cancer 5 (10.9%) 149 (16.5%) 0.31 16.2% 25.6% <0.001
Accident/violent 0 (0.0%) 15 (1.7%) 1.00 1.6% 2.8% 0.06
Dementia 0 (0.0%) 6 (0.7%) 1.00 0.6% 2.4% 0.001
Other 4 (8.7%) 88 (9.8%) 1.00 9.7% 21.1% <0.001
Unknown 22 (47.8%) 137 (15.2%) <0.001 16.8% – n/a
Total 46 (4.8%) 903 (95.2%) <0.001 100% 100% n/a
Data are presented as n (%). Statistical significance is at p<0.05/8=0.0063. CPAP: continuous positive airway pressure; OSAHS: obstructive
sleep apnoea–hypopnoea syndrome; n/a: not applicable.
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(OR=2.8, p=0.015 for males, OR=6.7, p=0.004 for females) (table 3). Age and AHI were also predictors of
mortality for both sexes. BMI, alcohol consumption and CPAP compliance were predictors of mortality
only for males, whereas smoking was a predictor of mortality only for females (table 3).
Figure 1 shows the cumulative survival of patients over long-term follow-up (years), split by CPAP use.
No observable difference in survival was noted until t=10 years. After this point, there was a steep decline
in survival in the non-CPAP group. Results were similar for each sex separately (supplementary figure 1a
and b). The survival curve split by OSAHS severity revealed a significant difference in survival between
patients with severe OSAHS, not on CPAP compared to less severe OSAHS (p<0.001) (figure 2). There
was no difference in survival between mild, moderate and severe OSAHS in patients on CPAP treatment
(p=0.92) (figure 3). These findings were consistent for both males and females (supplementary figures 2a
and b and 3a and b).
A significant association was found between CPAP use and length of survival (p<0.001). Those who used
CPAP for >5 years were 5.6-times more likely to survive than those not on CPAP (p<0.001). Similarly, the
mortality risk ratio showed that those who used CPAP for ⩽5 years were 3.1-times more likely to survive
than those in the non-CPAP arm (p<0.001). A statistically significant difference was also found in relative
mortality risk between those on long-term and short-term CPAP (RR=1.7, p<0.001) (table 4).
On follow-up, males were more likely to continue using CPAP compared to females (p<0.001) (table 5).
Patients not using CPAP were more likely to develop DMII (p=0.003), ischaemic heart disease (IHD)
(p<0.001) and suffer myocardial infarction (MI) (p<0.001) (table 5). Weight, BMI, AHI, A+H and
OSAHS severity were the most significant predictors of incident DMII, with BMI being a significant
predictor for both sexes (supplementary table 6). No significant predictors were identified for hypertension
(HTN) incidence (supplementary table 7), whereas age, smoking and CPAP compliance were significant
predictors of incident IHD in males (supplementary table 8).
Multivariate logistic regression analysis demonstrated that higher AHI was a significant predictor of
adherence to CPAP treatment (OR=1.02, 95% CI: 1.01–1.03, p=0.001) (supplementary table 9). Patients
with inability to fall asleep because of CPAP use were 2.99-times less likely to adhere to CPAP treatment
(95% CI: 1.64–5.48, p<0.001) (supplementary table 10). Mask issues led to 3.17-times less adherence to
CPAP treatment (95% CI: 1.68–5.99, p<0.001), while the strongest predictor of nonadherence was a bed
partner’s annoyance at the noise of the CPAP machine, with lowered adherence of 4.39-times (95% CI:
2.13–9.07, p<0.001) (supplementary table 10). No comorbidity increased CPAP treatment adherence.
However, respiratory comorbidity and MI lower adherence 1.46 (95% CI: 1.22–1.76, p<0.001) and 2.17
(95% CI: 1.59–2.98, p<0.001) times respectively (supplementary table 11).
TABLE 3 Results of logistic regression analysis affecting survival split by sex
Variable Males Females
OR 95% CI p-value OR 95% CI p-value
Age years 1.10 1.07–1.13 <0.001 1.12 1.06–1.18 <0.001
Weight kg 1.00 0.97–1.03 0.97 1.00 0.97–1.04 0.79
BMI kg·m−2 1.05 1.01–1.10 0.034 1.00 0.82–1.23 0.97
Smoking cigarettes per day 1.00 0.98–1.02 0.97 1.03 1.01–1.06 0.037
Alcohol units per week 1.02 1.01–1.04 0.010 1.01 0.91–1.12 0.86
ESS (n/24) 1.01 0.97–1.06 0.58 1.09 0.99–1.19 0.07
AHI (n) 1.02 1.01–1.03 0.014 1.02 1.01–1.03 0.012
OSAHS severity (mild/moderate/severe) 2.11 0.91–4.93 0.07 1.94 0.41–9.21 0.21
CPAP use (yes/no) 16.77 6.21–45.32 <0.001 10.94 3.16–37.82 <0.001
CPAP hours per night 1.31 1.19–1.44 <0.001 1.13 0.94–1.36 0.18
Type II diabetes mellitus (yes/no) 2.74 1.22–6.19 0.015 6.71 1.83–24.60 0.004
Respiratory condition (yes/no) 1.36 0.76–2.42 0.30 1.18 0.41–3.39 0.77
Depression/anxiety (yes/no) 1.36 0.68–2.74 0.39 1.22 0.37–3.99 0.74
Angina (yes/no) 2.56 0.66–9.85 0.17 4.33 0.67–28.09 0.12
Hypertension (yes/no) 1.18 0.67–2.08 0.56 1.36 0.47–3.93 0.57
Myocardial infarction (yes/no) 1.04 0.44–2.45 0.92 1.68 0.23–12.46 0.62
OR: odds ratio; CI: confidence intervals; BMI: body mass index; ESS: Epworth sleepiness scale; AHI:
apnoea–hypopnoea index; OSAHS: obstructive sleep apnoea–hypopnoea syndrome; CPAP: continuous
positive airway pressure.
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FIGURE 1 Survival curve showing cumulative survival in years, split by continuous positive airway pressure
(CPAP) use.
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FIGURE 2 Survival curve showing cumulative survival in years, split by obstructive sleep apnoea–hypopnoea
syndrome (OSAHS) severity in patients who were not on treatment with continuous positive airway pressure
(CPAP).
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Discussion
This study investigated factors affecting morbidity, mortality and adherence to CPAP treatment in a cohort
of OSAHS patients over an average follow-up period of 14.8±3.7 years. The main outcome was that CPAP
use reduced mortality and had a protective role in the incidence of DMII and cardiovascular
comorbidities. These observations have been well established by several previous cohort studies [3–5,
15–18]. Nevertheless, our study is the first to use imputation analysis in order to emulate a randomised,
controlled trial. This allows for removal of biases, namely immortal time bias on follow-up, a common
flaw in previous cohort studies.
We demonstrated that both long-term (>5 years) and short-term (⩽5 years) CPAP use substantially
reduced risk of death compared to non-CPAP use. Moreover, long-term CPAP use was significantly more
protective, regarding the risk of death, when compared to short-term use. This suggests that the benefits of
CPAP increase with longer-term use. The protective role of CPAP was evidenced by the fact that 95.2% of
deaths during the study period were in the No-CPAP arm of the cohort. CPAP use was a very strong
predictor for mortality in both males (OR=16.8) and females (OR=11).
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Mild, censored
Moderate, censored
25 30
Severe
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FIGURE 3 Survival curve showing cumulative survival in years, split by obstructive sleep apnoea–hypopnoea
syndrome (OSAHS) severity in patients under continuous positive airway pressure (CPAP) treatment.
TABLE 4 Results of imputation analysis of CPAP use and long-term survival in 4502 patients
CPAP use ratio Relative risk of mortality
ratio
Lower 95%
CI
Upper 95%
CI
p-value
No use/short-term use 3.14 2.69 3.66 <0.001
No use/long-term use 5.63 4.83 6.58 <0.001
Short-term use/long-term
use
1.74 1.49 2.02 <0.001
No use is defined as: patients who refused CPAP treatment (n=447). Short-term use is defined as: patients
who used CPAP for ⩽5 years. Long-term use is defined as: patients who used CPAP for > 5 years CPAP:
continuous positive airway pressure, CI: confidence interval.
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Previous cohort studies have shown female patients to have a lower morbidity and mortality rate than
males [3, 4], while CPAP use has been shown to improve survival in male patients but not in females [4,
5]. The results of our study demonstrate that females with OSAHS are at least as much at risk of death as
males and that CPAP use has a protective role in females too. Our findings mirror those reported by
CAMPOS-RODRIGUEZ et al. [17] reporting exclusively on females. A significant contributor to that could be
the fact that our cohort included a notable proportion of professional drivers who were mainly males and
had higher rates of adherence to CPAP treatment.
Cardiovascular and respiratory events were the main causes of death among OSAHS patients, more
common compared to the general population. The relationship between OSAHS and cardiovascular
mortality has been demonstrated in previous studies [3, 5, 15–18]. However, many previous studies were
methodologically limited, only including observational data and retrospective study designs. In this study,
the creation of clones allowed study participants to be compared against ‘healthy controls’. CPAP use in
OSAHS has a protective role against all-cause mortality as shown in this study and by others [19–21]. In
our study, respiratory events were a statistically significant more common cause of death among OSAHS
patients compared to the general population and CPAP use seemed to play a protective role (p=0.006).
We speculate that referral bias would have played a strong role in this observation, as the sleep centre was
initially a respiratory clinic, established in 1982, gradually evolving over the following decades. Changes in
lifestyle, health behaviour and the absence of many guidelines for positive pressure ventilation in
respiratory patients in the past may have also contributed to these results. By contrast, death from cancer
was significantly less common in OSAHS patients, a finding inconsistent with the results of several studies
published in the last 5 years [22–26].
At baseline, mean BMI was 31.8 kg·m−2 and 33.6 kg·m−2 in males and females respectively, indicating
obesity. Obesity has been linked to incident DMII, HTN and cardiovascular disease [27]. DMII was
significantly more prevalent in OSAHS patients not receiving CPAP therapy. Males and females who
developed diabetes were significantly heavier and had a higher mean AHI than those who did not develop
diabetes at follow-up. The mean BMI of all patients who developed DMII at follow-up and those who did
not were both in the obese range, which suggests there are more complex factors at play, including
baseline genetic and epigenetic risks, lifestyle, exercise and ethnic differences. Previous studies have shown
a dose–response relationship between OSAHS severity and blood pressure [28, 29]. In this cohort, no
significant predictors were identified for HTN incidence.
There is limited evidence in the literature for the association between smoking and OSAHS [30]. However,
smoking is a well-known risk factor for cardiovascular disease, such as IHD. As OSAHS greatly increases a
patient’s cardiovascular risk, it can be speculated that smoking may add to and interact with this increased
risk. This was confirmed in the present study which demonstrated that smoking was an independent
predictor of mortality for females with OSAHS and a predictor of developing IHD in patients with
OSAHS, both male and female. MARIN et al. [5] first reported increased cardiovascular mortality risk with
severe OSAHS, which normalised with CPAP therapy. Our cohort reflects these results, as OSAHS patients
without CPAP therapy had a significantly greater incidence of IHD and MI. In this cohort, no significant
association was found between OSAHS and risk of stroke. Current understanding of this association is
unclear, with CPAP treatment of OSAHS in stroke patients remaining controversial [31].
TABLE 5 Comparison of comorbidities at follow-up by CPAP use and by sex
Comorbidities On CPAP (n=895, 76.2%) No CPAP (n=279, 23.8%) p-value
Male (n=774, 86.5%) Female (n=121, 13.5%) p-value Male (n=215, 77.1%) Female (n=64, 22.9%) p-value <0.001
Type II diabetes mellitus 121/649 (18.6%) 20/105 (19.1%) 0.50 45/168 (26.8%) 17/54 (31.5%) 0.92 0.003
Hypertension 138/621 (22.2%) 15/80 (18.8%) 0.48 37/186 (19.9%) 14/59 (23.7%) 0.53 0.74
Ischaemic heart disease 82/659 (12.4%) 14/98 (14.3%) 0.61 47/161 (29.2%) 5/43 (11.6%) 0.20 <0.001
Angina 65/655 (9.9%) 13/97 (13.4%) 0.29 16/138 (11.6%) 2/40 (5.0%) 0.22 0.92
Myocardial infarction 29/659 (4.4%) 3/102 (2.9%) 0.49 35/198 (17.7%) 3/60 (5%) 0.02 <0.001
Heart failure 26/698 (3.7%) 4/107 (3.7%) 1.00 9/187 (4.8%) 0/57 (0.0%) 0.09 0.98
Atrial fibrillation 65/480 (13.5%) 6/67 (9.0%) 0.30 28/141 (19.9%) 7/41 (17.1%) 0.69 0.04
Stroke 43/721 (6.0%) 13/113 (11.5%) 0.03 23/204 (11.3%) 4/60 (6.7%) 0.30 0.06
Transient ischaemic attack 77/733 (10.5%) 12/108 (11.1%) 0.85 27/205 (13.2%) 5/60 (8.3%) 0.31 0.50
Smoking 44/312 (14.1%) 6/48 (12.5%) 0.77 18/99 (18.2%) 1/26 (3.9%) 0.07 0.72
Asthma 35/650 (5.4%) 10/81 (12.4%) 0.01 8/179 (4.5%) 5/47 (10.6%) 0.11 0.82
Data are presented as n/N (%). Statistical significance is at p<0.05/12=0.004. CPAP: continuous positive airway pressure.
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With regard to CPAP adherence, a higher AHI and fewer comorbidities were significantly more likely to
predict better long-term use in both males and females.
Proportionally, fewer women were entered into the study than men, which may have skewed some of the
comparative findings between the sexes. Recruitment was undertaken during a period when sleep medicine
was just climbing out of its infancy and general awareness may not have been so great, particularly among
females as well as referring doctors. Therefore, conclusions drawn from these results may be potentially
less reliable. Since patients cannot ethically be randomised to the non-CPAP group, we relied upon refusal
of treatment to create the ‘No-CPAP’ variable. This created a smaller sample size than the CPAP group,
possibly decreasing the reliability of our results by introducing type 2 errors. This could have also
introduced participant bias as non-CPAP users may have different needs, lifestyle choices, personality
types compared to CPAP users. It has been shown in previous studies that personality type may play a
significant role in CPAP adherence [32]. More specifically, patients with type D personality, assessed using
a 14-item questionnaire, the Type D Scale (DS14) [33], have poor compliance with treatment in general
[33], and particularly in the case of OSAHS, patients with type D personality are less likely to adhere to
CPAP and mandibular advancement devices (MADs) compared to those who do not have type D
personality [34, 35]. Patients with OSAHS with type D personality use their CPAP less than non-type D
personality OSAHS patients by 2 h per night (4 h versus 6 h) and are 45% less likely to use their MAD
treatment [34–36]. It has also been shown that OSAHS patients with higher scores on the depression and
hypochondriasis scales of the Minnesota Multiphasic Personality Inventory have lower adherence to CPAP
treatment [37]. Incomplete questionnaires and potential recall bias meant that not all variables were
available for each patient making sample sizes smaller than anticipated and occasionally not adequately
powered. Responder bias cannot be excluded from the follow-up cohort due to the low response rate for
the follow-up questionnaires (26%).
In conclusion, CPAP use is a significant predictor of long-term mortality and morbidity in the OSAHS
population. This was confirmed using imputation analysis, to allow for immortal time bias removal.
Emphasising the importance of diagnosing OSAHS and adherence to CPAP, in the form of public health
initiatives may be beneficial in reducing cardiometabolic disease burden in the community.
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